Stock News and Filings Feed


Add EDT
to your dashboard

Spectral Announces Second Quarter Results

2017-08-11 marketwired
TORONTO, ONTARIO--(Marketwired - Aug. 11, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2017.

Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position

2017-08-04 seekingalpha
CytoSorbents and Spectral Medical Inc. are two medical device companies that have much in common. One is based in US and the other in Canada. CytoSorbents is in the business of reducing ICU deaths from fatal inflammation. Spectral Medical Inc. is in the business of treating sepsis, “life-threatening organ dysfunction caused by a dysregulated host response to infection.”, which is the leading cause of ICU deaths globally.

FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review

2017-07-24 marketwired
TORONTO, ONTARIO--(Marketwired - July 24, 2017) - Spectral Medical Inc. (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced that the United States Food and Drug Administration ( "FDA") has accepted its rolling PMA application for Toraymyxin™ ("PMX") for review.

The Reasons Why Spectral Medical's Sepsis Treatment Will Not Receive An FDA Approval

2017-07-23 seekingalpha
Spectral's sepsis treatment deals with only one factor, of questionable importance, in a highly complex medical condition.

Daily Coverage on Healthcare Stocks: Spectral Medical, ProMIS Neurosciences, GeneNews, and Novadaq Technologies

2017-06-19 accesswire
LONDON, UK / ACCESSWIRE / June 19, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Medical Diagnostics & Research industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Spectral Medical, ProMIS Neurosciences, GeneNews, and Novadaq Technologies.

Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT

2017-06-12 marketwired
TORONTO, ONTARIO--(Marketwired - June 12, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that on June 14, 2017 at 11:30 am EDT (5:30 pm CEST), a special lecture entitled "Critical Care Nephrology Cases Presentation - Results of the EUPHRATES Trial", will be presented by Professor Massimo Antonelli at the 35th annual Vicenza Course on AKI (acute kidney injury) and CRRT(continuous renal replacement therapy) in Vicenza, Italy.

Spectral Announces Voting Results of Annual Meeting

2017-06-02 marketwired
TORONTO, ONTARIO--(Marketwired - June 1, 2017) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the "Meeting") of shareholders of the Corporation ("Shareholders") that was held yesterday, all six nominees for the board were elected, the voting results of which are as follows:

Spectral Files Final PMA Module for Toraymyxin(TM) With FDA

2017-05-30 marketwired
TORONTO, ONTARIO--(Marketwired - May 30, 2017) - Spectral Medical Inc., ("Spectral" or the "Company"), (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that it has submitted the fourth and final module of its PMA application to the United States Food and Drug Administration ("FDA") based on further analysis of the EUPHRATES trial - a randomized, blinded trial of patients in endotoxemic septic shock comparing use of Toraymyxin™ ("the PMX cartridge") versus sham hemoperfusion.

Spectral Announces First Quarter Results

2017-05-12 marketwired
TORONTO, ONTARIO--(Marketwired - May 12, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2017.

Research Reports Initiated on Healthcare Stocks: Spectral Medical, ProMIS Neurosciences, GeneNews, and Sernova

2017-05-01 accesswire
LONDON, UK / ACCESSWIRE / May 1, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include Spectral Medical, ProMIS Neurosciences, GeneNews, and Sernova.

Spectral Expands Distribution of EAA(TM) In the Middle and Far East and in Europe

2017-04-26 marketwired
TORONTO, ONTARIO--(Marketwired - April 26, 2017) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced the renewal and expansion of its exclusive distribution agreements with Toray Medical Co., Ltd. (TMC) and ESTOR SpA (ESTOR) for Spectral's rapid test for the assessment of endotoxin activity in human whole blood (EAA™).

U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

2017-03-07 marketwired
TORONTO, ONTARIO--(Marketwired - March 7, 2017) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it has received approval of the third module of its rolling PMA submission from the United States Food and Drug Administration ("FDA) for Toraymyxin™.

Spectral to File Final PMA Module With the FDA for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

2017-02-23 marketwired
TORONTO, ONTARIO--(Marketwired - Feb. 23, 2017) - Spectral Medical Inc., ("Spectral" or the "Company"), (TSX:EDT) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it plans to file the fourth of four modules of its premarket approval application (PMA) submission, containing the clinical study report, with the FDA for Toraymyxin™ early in the second quarter of this year.

Research Reports Initiated on Healthcare Stocks GeneNews, Spectral Medical, ProMIS Neurosciences, and Novadaq Technologies

2017-02-08 accesswire
LONDON, UK / ACCESSWIRE / February 8, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include GeneNews, Spectral Medical, ProMIS Neurosciences, and Novadaq Technologies.

Research Reports Initiated on Healthcare Stocks ProMIS Neurosciences, Novadaq Technologies, Spectral Medical, and GeneNews

2017-01-06 accesswire
LONDON, UK / ACCESSWIRE / January 6, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include ProMIS Neurosciences, Novadaq Technologies, Spectral Medical, and GeneNews.

Spectral Voluntarily Delists From OTCQX

2016-12-14 marketwired
TORONTO, ONTARIO--(Marketwired - Dec. 14, 2016) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective January 1, 2017.

Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors

2016-12-05 marketwired
TORONTO, ONTARIO--(Marketwired - Dec. 5, 2016) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced the appointment of Dr. Masayuki Kaneko as the Toray Industries, Inc. ("Toray") representative on its Board of Directors.

Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results

2016-11-11 marketwired
TORONTO, ONTARIO--(Marketwired - Nov. 11, 2016) - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced next steps in its development program for Toraymyxin™ (PMX) and released financial results for the third quarter ended September 30, 2016.

Research Reports Initiated on Healthcare Stocks Spectral Medical, GeneNews, ProMIS Neurosciences, and Novadaq Technologies

2016-11-04 accesswire
LONDON, UK / ACCESSWIRE / November 4, 2016 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include Spectral Medical, GeneNews, ProMIS Neurosciences, and Novadaq Technologies.

Most actively traded companies on the TSX

2016-10-03 winnipegfreepress
Spectral Medical Inc. (TSX:EDT). Medical diagnostics. Down $1.37, or 85.09 per cent, to 24 cents on 16.9-million shares.

Spectral Announces Clinical Trial Results

2016-10-03 marketwired
- Mortality benefit in the pre specified per protocol patient population with a MODS score greater than nine was 5%

Research Reports Initiated on Healthcare Stocks Neovasc, Titan Medical, ProMIS Neurosciences, and Spectral Medical

2016-09-26 accesswire
LONDON, UK / ACCESSWIRE / September 26, 2016 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Healthcare sector. Companies recently under review include Neovasc, Titan Medical, ProMIS Neurosciences, and Spectral Medical. Get all of our free research reports by signing up at: http://www.

Latest Reports on B2Gold, Knight Therapeutics, Lundin Mining, and Turquoise Hill Resources

2016-09-21 accesswire
NEW YORK, NY / ACCESSWIRE / September 21, 2016 / Canadian markets rose slightly Tuesday after comments made by Bank of Canada Governor Stephen Poloz hinted at a delay in a rise in interest rates due to economic struggles. The S&P/TSX Composite Index gained 0.18 percent to close at 14,521.98, while the S&P/TSX Venture Composite Index posted a gain of 0.19 percent to close at 803.21. The Financials and Materials sectors posted gains of 0.

Latest Reports on Spectral Medical, Painted Pony Petroleum, Seven Generations Energy, and Sleep Country Canada

2016-09-21 accesswire
NEW YORK, NY / ACCESSWIRE / September 21, 2016 / Canadian markets rose slightly Tuesday after comments made by Bank of Canada Governor Stephen Poloz hinted at a delay in a rise in interest rates due to economic struggles. The S&P/TSX Composite Index gained 0.18 percent to close at 14,521.98, while the S&P/TSX Venture Composite Index posted a gain of 0.19 percent to close at 803.21. The Financials and Materials sectors posted gains of 0.

Spectral Responds to Recent Trading Activity

2016-09-21 marketwired
TORONTO, ONTARIO--(Marketwired - Sept. 20, 2016) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF), at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release, they are not aware of any corporate developments that would cause the recent movement in the Company's share price.